South Korean Botox Firms Experienced U.S. Market Shifts
As South Korean aesthetic firms expand U.S. operations, shifting market strategies and regulatory hurdles change your options.
Updated on Oct. 7, 2026 in Beauty
Live Poll
Do you trust that increased competition among pharmaceutical companies will lower your healthcare costs?
South Korean companies are seeing divergent success in the U.S. botulinum toxin market as some firms rapidly expand and others face regulatory delays. This shift affects the availability and pricing of aesthetic treatments in a market that accounts for 60% of global toxin sales.
Why it matters
Changes in market players and pricing structures impact access to aesthetic procedures, while regulatory decisions continue to shape which products reach clinicians. As the U.S. market grows toward a projected 11.53 billion dollars by 2033, these shifts influence the cost and variety of treatments offered to patients.
Data reflects that Daewoong Pharmaceutical captured 14% of the U.S. aesthetic toxin market in 2025. While market growth continues, the U.S. regulatory status of competitor Medytox remains unresolved following an FDA rejection in February 2025.
The players
Daewoong Pharmaceutical
A South Korean biopharmaceutical company focused on producing botulinum toxin products for aesthetic and therapeutic markets.
Hugel
A South Korean manufacturer of aesthetic products currently transitioning to a direct sales system for its toxin offerings in the U.S.
Medytox
A biopharmaceutical entity that has faced U.S. regulatory delays and ongoing legal disputes regarding its toxin manufacturing and distribution.
The details
South Korean firms are employing different commercial strategies to gain a foothold in the U.S. aesthetic sector. Daewoong Pharmaceutical utilizes a distribution partnership to offer products at lower prices, while Hugel is moving toward a direct sales model to manage its own product distribution. These companies are also exploring therapeutic applications for toxins beyond cosmetic use to expand their medical footprint.
Timeline
2019: Daewoong Pharmaceutical entered the U.S. market.
December 2023: Medytox applied for FDA approval of MT10109L.
February 2025: FDA rejected the Medytox application.
July 2026: Hugel began direct sales in the U.S.
Health Landscape
The entry of new manufacturers marks a departure from a market long dominated by a few established brands. Companies are now navigating the FDA's biological equivalence review process to compete directly in the therapeutic and aesthetic spaces.
Increased competition among toxin manufacturers may lead to a wider range of pricing options for aesthetic patients. Discuss with your doctor which specific products are available at your clinic and whether they meet your individual treatment goals.
The takeaway
The botulinum toxin market is becoming more crowded as diverse global manufacturers compete for U.S. market share. If you are considering aesthetic treatments, ask your clinician about the specific products used and how they compare in terms of clinical history and intended results.
What happens next
Daewoong Pharmaceutical expects to submit an Investigational New Drug application in Q4 2026, with plans to begin clinical trials for therapeutic applications in Q1 2027.
Further reading
For more on the latest developments in aesthetic medicine, explore our coverage of Beauty.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you trust that increased competition among pharmaceutical companies will lower your healthcare costs?
